Skip to content

The Effect of Oxycodone Combined with Dexmedetomidine on Analgesic Efficacy, Stress Response, and Postoperative Cognitive Function in Elderly Patients Undergoing Knee Arthroplasty: A Prospective, Single-Center, Randomized Controlled Trial

The Effect of Oxycodone Combined with Dexmedetomidine on Analgesic Efficacy, Stress Response, and Postoperative Cognitive Function in Elderly Patients Undergoing Knee Arthroplasty: A Prospective, Single-Center, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116704
Enrollment
Unknown
Registered
2026-01-14
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly knee arthroplasty

Interventions

Oxycodone Group:At 2 minutes before skin incision, patients in the Oxycodone Group received an intravenous injection of oxycodone at a dose of 0.02 mg/kg.
Control Group:At 2 minutes before skin incision, patients in the Control Group received an intravenous injection of sufentanil at a dose of 0.1 µg/kg.

Sponsors

Special Scientific Research Fund of Wu Jieping Medical Foundation
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 65 years old, American Society of Anesthesiologists (ASA) physical status ?~?, body mass index (BMI) 18.5~30 \mathrm{kg/m^2}; 2. Elderly patients scheduled for elective knee arthroplasty; 3. Informed consent obtained from patients and their family members.

Exclusion criteria

Exclusion criteria: 1. Preoperative pulse oxygen saturation (SpO2) < 90% or arterial partial pressure of oxygen (PaO2) <= 60 mmHg; 2. Patients with allergy to opioids, a history of opioid addiction, or participation in other clinical studies; 3. Patients with a history of epilepsy or depression; 4. Patients with severe organ dysfunction or failure (e.g., liver failure, renal failure, respiratory failure, etc.); 5. Patients with severe infection; 6. Patients with severe mental system diseases who cannot cooperate with the study or are taking antipsychotic drugs; 7. Patients who are deemed ineligible for participation in this study by the researchers for other reasons.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale (VAS);Number of PCA pump presses within 48h postoperatively;Rescue analgesia status within 48h postoperatively;Adverse reaction occurrence status within 48h postoperatively;Homocysteine (Hcy) concentration in peripheral venous blood;Mini-Mental State Examination (MMSE);

Secondary

MeasureTime frame
Stress response indicators;S100ß protein in peripheral venous blood;Neuron-Specific Enolase (NSE) in peripheral venous blood;

Countries

China

Contacts

Public ContactLing Yunzhi

The First Affiliated Hospital of Bengbu Medical University

lingyunzhi770916@aliyun.com+86 152 5525 0001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026